北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 肾内科  > 期刊论文
学科主题: 临床医学
题名:
Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China
作者: Xu, Jing1; Zhang, Yi-Xiang1; Yu, Xue-Qing2; Liu, Zhi-Hong3; Wang, Li-Ning4; Chen, Jiang-Hua5; Fan, Ya-Ping6; Ni, Zhao-Hui7; Wang, Mei8; Yuan, Fa-Huan9,10; Ding, Guo-Hua11; Chen, Xiang-Mei12,13; Zhang, Ai-Ping14; Mei, Chang-Lin1
关键词: Lanthanum carbonate ; Hyperphosphatemia ; Chronic kidney disease 5D ; Hemodialysis ; Continuous ambulatory peritoneal dialysis (CAPD)
刊名: BMC NEPHROLOGY
发表日期: 2013-02-04
DOI: 10.1186/1471-2369-14-29
卷: 14
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Urology & Nephrology
研究领域[WOS]: Urology & Nephrology
关键词[WOS]: CHRONIC KIDNEY-DISEASE ; CHRONIC-HEMODIALYSIS PATIENTS ; ORAL PHOSPHATE BINDERS ; SERUM-CALCIUM LEVELS ; MORTALITY RISK ; DIALYSIS PATIENTS ; PHOSPHORUS ; EFFICACY ; ASSOCIATION ; FAILURE
英文摘要:

Background: Serum phosphorus control is critical for chronic kidney disease (CKD) 5D patients. Currently, clinical profile for an oral phosphorus binder in the mainland Chinese population is not available.

Objective: To establish the efficacy, safety, and tolerability of lanthanum carbonate in CKD 5D patients.

Design: Multicenter, randomized, double blind, placebo-controlled study. A central randomization center used computer generated tables to allocate treatments.

Setting: Twelve tertiary teaching hospitals and medical university affiliated hospitals in mainland China.

Participants: Overall, 258 hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) adult patients were enrolled.

Intervention: After a 0-3-week washout period and a 4-week lanthanum carbonate dose-titration period, 230 patients were randomized 1: 1 to receive lanthanum carbonate (1500 mg-3000 mg) or placebo for a further 4-week maintenance phase.

Main outcome measures: Efficacy and safety of lanthanum carbonate to achieve and maintain target serum phosphorus concentrations were assessed.

Results: In the titration phase, serum phosphorus concentrations of all patients decreased significantly. About three-fifths achieved target levels without significantly disturbing serum calcium levels. At the end of the maintenance period, the mean difference in serum phosphorus was significantly different between the lanthanum carbonate and placebo-treated groups (0.63+/-0.62 mmol/L vs. 0.15+/-0.52 mmol/L, P < 0.001). The drug-related adverse effects were mild and mostly gastrointestinal in nature.

Conclusion: Lanthanum carbonate is an efficacious and well-tolerated oral phosphate binder with a mild AE profile in hemodialysis and CAPD patients. This agent may provide an alternative for the treatment of hyperphosphatemia in CKD 5D patients in mainland China.

语种: 英语
所属项目编号: B902 ; 08dz1900600 ; 81200499 ; 12ZR1454700
项目资助者: Fresenius-Kabi (China) Co., Ltd. ; Shanghai Key Discipline Project ; Shanghai Science and Technology Commission Major Research Project ; National Nature Science Fund of China ; Nature Science Fund of Shanghai
WOS记录号: WOS:000314833700001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53891
Appears in Collections:北京大学第二临床医学院_肾内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Mil Med Postgrad Coll, Beijing, Peoples R China
2.Second Mil Med Univ, Changzheng Hosp, Dept Nephrol, Shanghai, Peoples R China
3.Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou, Guangdong, Peoples R China
4.Nanjing Univ, Jingling Hosp, Sch Med, Dept Nephrol,Inst Kidney Dis Chinese Peoples Libe, Nanjing 210008, Jiangsu, Peoples R China
5.China Med Univ, Affiliated Hosp 1, Dept Nephrol, Shenyang, Peoples R China
6.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou 310003, Zhejiang, Peoples R China
7.Nantong Med Coll, Affiliated Hosp, Dept Nephrol, Nantong, Jiangsu, Peoples R China
8.Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Renal, Shanghai 200030, Peoples R China
9.Peking Univ, Peoples Hosp, Dept Nephrol, Beijing 100871, Peoples R China
10.Third Mil Med Univ, Xinqiao Hosp, Inst Nephrol Chongqing, Chongqing, Peoples R China
11.Third Mil Med Univ, Xinqiao Hosp, Dept Nephrol, Chongqing, Peoples R China
12.Wuhan Univ, Renmin Hosp, Dept Nephrol, Wuhan 430072, Peoples R China
13.Chinese Peoples Liberat Army Gen Hosp, Chinese PLA Inst Nephrol, Beijing, Peoples R China
14.Gen Hosp Jinan Mil Command, Dept Nephrol, Jinan, Shandong, Peoples R China

Recommended Citation:
Xu, Jing,Zhang, Yi-Xiang,Yu, Xue-Qing,et al. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China[J]. BMC NEPHROLOGY,2013,14.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Xu, Jing]'s Articles
[Zhang, Yi-Xiang]'s Articles
[Yu, Xue-Qing]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Xu, Jing]‘s Articles
[Zhang, Yi-Xiang]‘s Articles
[Yu, Xue-Qing]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace